STOCK TITAN

Merus N.V - MRUS STOCK NEWS

Welcome to our dedicated news page for Merus N.V (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus N.V.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merus N.V's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merus N.V's position in the market.

Rhea-AI Summary
Merus N.V. announced financial results for Q3 2023 and provided a business update. The company plans to submit potential BLA applications for its Zeno and petosemtamab programs. Clinical data for Zeno in NRG1+ NSCLC and PDAC show robust efficacy. The company also raised $172M in a public offering, with existing funds expected to support operations into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.4%
Tags
-
Rhea-AI Summary
Merus N.V. announced that its CEO, Bill Lundberg, will participate in two investor conferences: BMO Biopharma Spotlight Series: Oncology Day on November 8 and Stifel 2023 Healthcare Conference on November 14. The BMO conference will have a fireside chat with no live webcast, while the Stifel conference will have a live webcast. Archived presentations will be available on the company's website for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
conferences
-
Rhea-AI Summary
Merus N.V. announces interim clinical data for zenocutuzumab in NRG1+ cancer patients, showing promising results and potential for BLA submissions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none
Rhea-AI Summary
Merus N.V. announces the acceptance of abstracts on bispecific antibodies MCLA-129 and zenocutuzumab for presentation at the ESMO Asia Congress 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
-
Rhea-AI Summary
Merus N.V. CEO to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
conferences
-
Rhea-AI Summary
Merus N.V. announces the pricing of an underwritten public offering of 6,818,182 common shares at $22.00 per share, with an option for the underwriters to purchase an additional 1,022,727 common shares. The gross proceeds from the offering are expected to be approximately $150.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
Rhea-AI Summary
Merus N.V. (Nasdaq: MRUS) has announced the launch of a proposed underwritten public offering of its common shares to advance the clinical development of its product candidates and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
-
Rhea-AI Summary
Merus N.V. announces financial results for Q2 and provides business update. Petosemtamab granted Fast Track Designation for head & neck cancer. Breakthrough Therapy Designations granted for Zeno in lung and pancreatic cancer. Merus plans to initiate phase 3 trial of petosemtamab in mid-2024. Enrollment continues for Zeno and MCLA-129 trials. Merus working with Incyte Corporation on bispecific antibody programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.34%
Tags
-
Rhea-AI Summary
Merus N.V., a clinical-stage oncology company, announced that two abstracts featuring updated interim clinical data for its targeted bispecific antibody, zenocutuzumab (Zeno), have been selected for presentation at the European Society for Medical Oncology Congress (ESMO) 2023. The abstracts will focus on NRG1+ non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). Merus is currently enrolling patients for the phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
Rhea-AI Summary
Merus N.V. has received Breakthrough Therapy Designation (BTD) from the FDA for zenocutuzumab (Zeno) for the treatment of NRG1+ non-small cell lung cancer. This follows previous designations for pancreatic cancer and metastatic solid tumors harboring NRG1 gene fusions. Merus plans to engage in discussions with the FDA for expedited development and review, and will provide updates on the potential Biologics License Application (BLA) submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
none
Merus N.V

Nasdaq:MRUS

MRUS Rankings

MRUS Stock Data

2.46B
42.51M
7.18%
88.09%
5.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Netherlands
Utrecht

About MRUS

merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.